Chapter 8 Folate Receptor Expression in Pituitary Adenomas. Cellular and Molecular Analysis

Vitamins and Hormones

Volumn 79, Issue , 2008, Pages 235-266

  Evans, Chheng Orn ^a   Yao, Congjun ^a   LaBorde, David ^a   Oyesiku, Nelson M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; FOLIC ACID; FOLR1 PROTEIN, MOUSE; MESSENGER RNA; NOTCH RECEPTOR; NOTCH3 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ADENOMA; ADULT; AGED; ANIMAL; ARTICLE; CELL LINE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HYPOPHYSIS TUMOR; MALE; METABOLISM; MIDDLE AGED; MOUSE; MUTATION; PROTEIN BINDING;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL LINE; CELL PROLIFERATION; FEMALE; FOLIC ACID; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MIDDLE AGED; MUTATION; PITUITARY NEOPLASMS; PROTEIN BINDING; RECEPTORS, CELL SURFACE; RECEPTORS, NOTCH; RNA, MESSENGER;

EID: 51849163230     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(08)00408-1     Document Type: Review

References (53)

1. Antony A.C. The biological chemistry of folate receptors. Blood 79 (1992) 2807-2820
2. Asa S. Tumors of the Pituitary Gland (1998), Armed Forces institute of Pathology, Washington, DC
3. Asa S.L., and Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr. Rev. 19 (1998) 798-827
4. Asa S.L., and Kovacs K. Clinically non-functioning human pituitary adenomas. Can. J. Neurol. Sci. 19 (1992) 228-235
5. Asa S.L., Cheng Z., Ramyar L., Singer W., Kovacs K., Smyth H.S., and Muller P. Human pituitary null cell adenomas and oncocytomas in vitro: Effects of adenohypophysiotropic hormones and gonadal steroids on hormone secretion and tumor cell morphology. J. Clin. Endocrinol. Metab. 74 (1992) 1128-1134
6. Bagnoli M., Tomassetti A., Figini M., Flati S., Dolo V., Canevari S., and Miotti S. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor over-expression. Oncogene 19 (2000) 4754-4763
7. Bellavia D., Campese A.F., Checquolo S., Balestri A., Biondi A., Cazzaniga G., Lendahl U., Fehling H.J., Hayday A.C., Frati L., von Boehmer H., Gulino A., et al. Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc. Natl. Acad. Sci. USA 99 (2002) 3788-3793
8. Black P.M., Hsu D.W., Klibanski A., Kliman B., Jameson J.L., Ridgway E.C., Hedley-Whyte E.T., and Zervas N.T. Hormone production in clinically nonfunctioning pituitary adenomas. J. Neurosurg. 66 (1987) 244-250
9. Bottero F., Tomassetti A., Canevari S., Miotti S., Menard S., and Colnaghi M.I. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res. 53 (1993) 5791-5796
10. Bradshaw C., and Kakar S. Pituitary tumor transforming gene: An important gene in normal cellular functions and tumorigenesis. Histol. Histopathol. 22 (2007) 219-226
11. Chaidarun S.S., Eggo M.C., Sheppard M.C., and Stewart P.M. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 135 (1994) 2012-2021
12. Chung K.N., Saikawa Y., Paik T.H., Dixon K.H., Mulligan T., Cowan K.H., and Elwood P.C. Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates. J. Clin. Invest. 91 (1993) 1289-1294
13. Dang L., Fan X., Chaudhry A., Wang M., Gaiano N., and Eberhart C. Notch3 signaling initiates choroid plexus tumor formation. Oncogene 25 (2006) 487-491
14. Dang T.P., Eichenberger S., Gonzalez A., Olson S., and Carbone D.P. Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene 22 (2003) 1988-1997
15. Doucette M.M., and Stevens V.L. Folate receptor function is regulated in response to different cellular growth rates in cultured mammalian cells. J. Nutr. 131 (2001) 2819-2825
16. Evans C.O., Young A.N., Brown M.R., Brat D.J., Parks J.S., Neish A.S., and Oyesiku N.M. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J. Clin. Endocrinol. Metab. 86 (2001) 3097-3107
17. Evans C.O., Reddy P., Brat D.J., O'Neill E.B., Craige B., Stevens V.L., and Oyesiku N.M. Differential expression of folate receptor in pituitary adenomas. Cancer Res. 63 (2003) 4218-4224
18. Figini M., Ferri R., Mezzanzanica D., Bagnoli M., Luison E., Miotti S., and Canevari S. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther. 10 (2003) 1018-1025
19. Fukui S., Otani N., Nawashiro H., Yano A., Nomura N., Miyazawa T., Ohnuki A., Tsuzuki N., Katoh H., Ishihara S., and Shima K. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas. Brain Tumor Pathol. 19 (2002) 23-29
20. Gao Y., Qian W., Dark K., Toraldo G., Lin A., Guldberg R., Flavell R., Weitzmann M., and Pacifici R. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc. Natl. Acad. Sci. USA 101 (2004) 16618-16623
21. Gittoes N.J. Current perspectives on the pathogenesis of clinically non-functioning pituitary tumours. J. Endocrinol. 157 (1998) 177-186
22. Gittoes N.J., McCabe C.J., Sheppard M.C., and Franklyn J.A. Estrogen receptor beta mRNA expression in normal and adenomatous pituitaries. Pituitary 1 (1999) 99-104
23. Grbavec D., Lo R., Liu Y., and Stifani S. Transducin-like enhancer of split 2, a mammalian homologue of Drosophila Groucho, act as a transcriptional repressor, interacts with hairy/enhancer of split proteins, and is expressed during neuronal development. Eur. J. Biochem. 258 (1998) 339-349
24. Greenman Y., and Melmed S. Diagnosis and management of nonfunctioning pituitary tumors. Annu. Rev. Med. 47 (1996) 95-106
25. Hasson P., and Paroush Z. Crosstalk between the EGFR and other signalling pathways at the level of the global transcriptional corepressor Groucho/TLE. Br. J. Cancer 94 (2006) 771-775
26. Horejsi V., Drbal K., Cebecauer M., Cerny J., Brdicka T., Angelisova P., and Stockinger H. GPI-microdomains: A role in signalling via immunoreceptors. Immunol. Today 20 (1999) 356-361
27. Hough C., Cho K., Zonderman A., Schwartz D., and Morin P. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 61 (2001) 3869-3876
28. Ilangumaran S., He H., and Hoessli D. Microdomains in lymphocyte signalling: Beyond GPI-anchored proteins. Immunol. Today 21 (2000) 2-7
29. Jhaveri M., Rait A., Chung K., Trepel J., and Chang E. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol. Cancer Ther. 3 (2004) 1505-1512
30. Kane M.A., Portillo R.M., Elwood P.C., Antony A.C., and Kolhouse J.F. The influence of extracellular folate concentration on methotrexate uptake by human KB cells. Partial characterization of a membrane-associated methotrexate binding protein. J. Biol. Chem. 261 (1986) 44-49
31. Katznelson L., Alexander J.M., and Klibanski A. Clinical review 45: Clinically nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 76 (1993) 1089-1094
32. Kelley K., Rowan B., and Ratnam M. Modulation of the folate receptor alpha gene by the estrogen receptor: Mechanism and implications in tumor targeting. Cancer Res. 63 (2003) 2820-2828
33. Luhrs C.A., Raskin C.A., Durbin R., Wu B., Sadasivan E., McAllister W., and Rothenberg S.P. Transfection of a glycosylated phosphatidylinositol-anchored folate-binding protein complementary DNA provides cells with the ability to survive in low folate medium. J. Clin. Invest. 90 (1992) 840-847
34. Mathias C.J., and Green M.A. A kit formulation for preparation of [(111)In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. Nucl. Med. Biol. 25 (1998) 585-587
35. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., and Green M.A. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med. 39 (1998) 1579-1585
36. McCabe C., Boelaert K., Tannahill L., Heaney A., Stratford A., Khaira J., Hussain S., Sheppard M., Franklyn J., and Gittoes N. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J. Clin. Endocrinol. Metab. 87 (2002) 4238-4244
37. McCabe C., Khaira J., Boelaert K., Heaney A., Tannahill L., Hussain S., Mitchell R., Olliff J., Sheppard M., Franklyn J., and Gittoes N. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: Relationships to clinical tumour behaviour. 1: Clin Endocrinol (Oxf). 2003 Feb. 58 (2003) 141-150
38. Miotti S., Canevari S., Menard S., Mezzanzanica D., Porro G., Pupa S.M., Regazzoni M., Tagliabue E., and Colnaghi M.I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer 39 (1987) 297-303
39. Miotti S., Bagnoli M., Tomassetti A., Colnaghi M.I., and Canevari S. Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J. Cell Sci. 113 (2000) 349-357
40. Moreno C.S., Evans C.O., Zhan X., Okor M., Desiderio D.M., and Oyesiku N.M. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 65 (2005) 10214-10222
41. Onguru O., Scheithauer B., Kovacs K., Vidal S., Jin L., Zhang S., Ruebel K., and Lloyd R. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod. Pathol. 17 (2004) 772-780
42. Orr R.B., and Kamen B.A. UMSCC38 cells amplified at 11q13 for the folate receptor synthesize a mutant nonfunctional folate receptor. Cancer Res. 54 (1994) 3905-3911
43. Orr R.B., and Kamen B.A. Identification of a point mutation in the folate receptor gene that confers a dominant negative phenotype. Cancer Res. 55 (1995) 847-852
44. Rijnboutt S., Jansen G., Posthuma G., Hynes J.B., Schornagel J.H., and Strous G.J. Endocytosis of GPI-linked membrane folate receptor-alpha. J. Cell Biol. 132 (1996) 35-47
45. Rochman H., Selhub J., and Karrison T. Folate binding protein and the estrogen receptor in breast cancer. Cancer Detect Prev. 8 (1985) 71-75
46. Ross J.F., Chaudhuri P.K., and Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73 (1994) 2432-2443
47. Semba S., Han S.Y., Ikeda H., and Horii A. Frequent nuclear accumulation of beta-catenin in pituitary adenoma. Cancer 91 (2001) 42-48
48. Shen F., Ross J.F., Wang X., and Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 33 (1994) 1209-1215
49. Sun X.L., Murphy B.R., Li Q.J., Gullapalli S., Mackins J., Jayaram H.N., Srivastava A., and Antony A.C. Transduction of folate receptor cDNA into cervical carcinoma cells using recombinant adeno-associated virions delays cell proliferation in vitro and in vivo. J. Clin. Invest. 96 (1995) 1535-1547
50. Sun X.L., Jayaram H.N., Gharehbaghi K., Li Q.J., Xiao X., and Antony A.C. Modulation of the cytotoxicity of 3′-azido-3′-deoxythymidine and methotrexate after transduction of folate receptor cDNA into human cervical carcinoma: Identification of a correlation between folate receptor expression and thymidine kinase activity. Cancer Res. 59 (1999) 940-946
51. Toffoli G., Cernigoi C., Russo A., Gallo A., Bagnoli M., and Boiocchi M. Over-expression of folate binding protein in ovarian cancers. Int. J. Cancer 74 (1997) 193-198
52. Wang D., Zhang H., Lang F., and Yun C. Acute activation of NHE3 by dexamethasone correlates with activation of SGK1 and requires a functional glucocorticoid receptor. Am. J. Physiol. Cell Physiol. 292 (2007) C396-C404
53. Yamada S., Asa S.L., Kovacs K., Muller P., and Smyth H.S. Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay. J. Clin. Endocrinol. Metab. 68 (1989) 73-80